Faeth Therapeutics (NASDAQ: FTH) has reported preliminary Phase 2 clinical results showing a confirmed objective response rate of 33% for its investigational PIKTOR treatment combined with paclitaxel in patients with...
Kyverna Therapeutics (NASDAQ: KYTX) has announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS)...
In a recent LinkedIn post, Dr. Riam Shammaa, CEO of closely held Cell Technologies, and co-author of a recently published paper in Frontiers in Immunology, highlighted findings from an investigation into whether...
Azora Therapeutics (NASDAQ: AZR) has announced the formation of a five-member board of directors comprising individuals with extensive drug development experience, a track record of FDA approvals, public-company...
Opus Genetics (NASDAQ: IRD) has announced the completion of dosing in the higher-dose Cohort 2 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases...
Altimmune (NASDAQ: ALT) has announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted...
Analysts for Raymond James and Lake Street Capital Markets say the CMS Final Rule released last evening is a win for Profound Medical (NASDAQ:PROF; TSX:PRN), confirming “very strong reimbursement” for the company’s...
Profound Medical (NASDAQ: PROF; TSX: PRN) has seen the first MRI-guided prostate cancer treatment performed using its TULSA-PRO system at the Mātai Medical Research Institute in Gisborne, New Zealand, following its...
Lucid Diagnostics (NASDAQ: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), has announced a peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer...
Pasithea Therapeutics (NASDAQ: KTTA) has announced that the FDA has cleared its Investigational New Drug (IND) application for a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with NF1...
Closely held Specific Biologics has announced the closing of an oversubscribed $35 million Series A financing. The round was led by Hatteras Venture Partners, with participation from foundational investors Lumira...
HeartBeam (NASDAQ: BEAT) has revealed positive results today from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment presented by Graham Nichol, MD, MPH, FRCP(C), of the University of...